SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-23-001807
Filing Date
2023-05-11
Accepted
2023-05-11 06:07:26
Documents
28
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q zk2329603.htm   iXBRL 10-Q 625637
2 CERTIFICATION PURSUANT TO exhibit_31-1.htm EX-31.1 17610
3 EXHIBIT 31.2 exhibit_31-2.htm EX-31.2 18433
4 CERTIFICATION PURSUANT TO exhibit_32-1.htm EX-32.1 7517
5 CERTIFICATION PURSUANT TO exhibit_32-2.htm EX-32.2 7407
  Complete submission text file 0001178913-23-001807.txt   1924474

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cmmb-20230331.xsd EX-101.SCH 18695
7 XBRL CALCULATION FILE cmmb-20230331_cal.xml EX-101.CAL 25775
8 XBRL DEFINITION FILE cmmb-20230331_def.xml EX-101.DEF 46272
9 XBRL LABEL FILE cmmb-20230331_lab.xml EX-101.LAB 206959
10 XBRL PRESENTATION FILE cmmb-20230331_pre.xml EX-101.PRE 92728
22 EXTRACTED XBRL INSTANCE DOCUMENT zk2329603_htm.xml XML 84261
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

IRS No.: 813676773 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38807 | Film No.: 23908662
SIC: 2834 Pharmaceutical Preparations